| 1. |
Loffet, A. (2002) Peptides as drugs: is there a market? J. Pept. Sci.
8, 1–7.
|
| |
| 2. |
Jones, R. M., and Bulaj, G. (2000) Conotoxins—new vistas for peptide therapeutics. Curr. Pharm. Des. 6, 1249–1285.
|
| |
| 3. |
Cudic, M. and Otvos, L., Jr. (2002) Intracellular targets of antibacterial peptides. Curr. Drug Targets
3, 101–106.
|
| |
| 4. |
Zasloff, M. (2002) Antimicrobial peptides of multicellular organisms. Nature
415, 389–395.
|
| |
| 5. |
Sabath, L. D. (1976) The assay of antimicrobial compounds. Hum. Pathol. 7, 287–185.
|
| |
| 6. |
Amsterdam, D. (1996) Susceptibility testing of antimicrobials in liquid media, in: Antibiotics in Laboratory Medicine (Loman, V., ed). Williams and Wilkins, Philadelphia, PA: pp. 52–111.
|
| |
| 7. |
Rahman, M., Kuhn, I., Rahman, M., Olsson-Liljequist, B., and Mollby, R. (2004) Evaluation of a scanner-assisted colorimetric
MIC method for susceptibility testing of gram-negative fermentative bacteria. Appl. Environment. Microbiol. 70, 2398–2403.
|
| |
| 8. |
Otvos, L., Jr. (2000) Antibacterial peptides isolated from insects. J. Pept. Sci. 6, 497–511.
|
| |
| 9. |
Stubbings, W. J., Bostock, J. M., Ingham, E., and Chopra, I. (2004) Assessment of a microplate method for determining the
post-antibiotic effect in Staphylococcus aureus and Escherichia coli. J. Antimicrob Chemother. 54, 139–143.
|
| |
| 10. |
Rajagopal, S., Eis, N., and Nickerson, K. W. (2003) Eight gram-negative bacteria are 10,000 times more sensitive to cationic
detergents than to anionic detergents. Can. J. Microbiol. 49, 775–779.
|
| |
| 11. |
Krisher, K. K. and Linscott, A. (1994) Comparison of three commercial MIC systems, E test, fastidious antimicrobial susceptibility
panel, and FOX fastidious panel, for confirmation of penicillin and cephalosporin resistance in Streptococcus pneumoniae. J. Clin. Microbiol.
32, 2242–2245.
|
| |
| 12. |
Virella, G. (1996) Microbiology and Infectious Diseases. Williams and Wilkins, Philadelphia, PA.
|
| |
| 13. |
National Committee for Clinical Laboratory Standards (1997) Methods for dilution antimicrobial susceptibility tests for bacteria
that grow aerobically, 4th ed. Approved standard M7–A4. National Committee for Clinical Laboratory Standards, Wayne, PA.
|
| |
| 14. |
Cudic, M., Condie, B. A., Weiner, D. J., et al. (2002) Development of novel antibacterial peptides that kill resistant clinical
isolates. Peptides
23, 271–283.
|
| |
| 15. |
Cudic, M., Lockatell, C. V., Johnson, D. E., and Otvos, L., Jr. (2003) In vitro and in vivo activity of a designed antibacterial
peptide analog against uropathogens. Peptides
24, 807–820.
|
| |
| 16. |
Otvos, L., Jr., Snyder, C., Condie, B., Bulet, P., and Wade, J. D. (2005) Chimeric antimicrobial peptides exhibit multiple
modes of action. Int. J. Pept. Res. Ther.
11, 29–42.
|
| |
| 17. |
Powell, M. F., Stewart, T., Otvos, L., Jr., et al. (1993) Peptide stability in drug development. II. Effect of single amino
acid substitution and glycosylation on peptide reactivity in human serum. Pharm. Res. 10, 1268–1273.
|
| |
| 18. |
Gennaro, R., Zanetti, M., Benincasa, M., Podda, E., and Miani, M. (2002) Pro-rich antimicrobial peptides from animals: structure,
biological functions and mechanism of action. Curr. Pharm. Des. 8, 763–778.
|
| |
| 19. |
Ge, Y., MacDonald, D. L., Holroyd, K. J., Thornsberry, C., Wexler, H., and Zasloff, M. (1999) In vitro properties of pexiganan,
and analog of magainin. Antimicrob. Agents Chemother. 43, 782–788.
|
| |